Drug Profile
SAR 125844
Alternative Names: SAR-125844Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Sanofi
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Solid tumours
Most Recent Events
- 24 Sep 2021 Discontinued - Phase-I for Solid tumours in USA, France, Spain, Italy, South Korea, Japan (IV) (Sanofi pipeline, September 2021)
- 24 Sep 2021 Discontinued - Phase-II for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Czech Republic, France, Netherlands, Poland, Spain, Germany, Italy, Greece, Belgium, Austria, Hungary (IV) (Sanofi pipeline, September 2021)
- 01 Jan 2016 Sanofi completes a phase I trial in Solid tumours in Japan and South Korea (NCT01657214)